Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Authors Solvay Pharmaceuticals
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Links Registry of Trials

This article is included in 2 Systematic reviews Systematic reviews (2 references)

This article is part of the following publication threads:
This article is part of the following matrixes of evidence:
Loading references information
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.
Epistemonikos ID: 63217294ad6f82eba11cb8619ef62b473799d522
First added on: Jun 26, 2015